Ethel Weld, MD

CRS:

JHU

Role:

Email:

eweld@jhmi.edu
  • Protocol chair, IMPAACT 2005
  • Protocol vice-chair, IMPAACT 2022
  • Member, Clinical Pharmacology Advisory Group of the ACTG Laboratory Steering Committee (2018-Present)
  • Member, ACTG Antiretroviral Therapy Strategies Transformative Science Group Less Frequent Dosing ART Working Group
  • Member, Pharmacology Core, HPTN Laboratory Core
  • Member, TB in Pregnancy Working Group
  • Protocol pharmacologist for HPTN 086, IMPAACT CAP 544, IMPAACT CAP 543

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5300/P2003: PHOENIx Feasibility Study

Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design

Read More

NWCS 414, Evaluation of a Serum Biosignature for Identifying...

We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...

Read More

NWCS 445: Novel Biomarkers to Shorten TB Treatment

Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...

Read More

A5225: Phase I/II Dose-Finding Study of High-Dose...

A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...

Read More

A5282: A Randomized, Phase II Trial to Compare an HPV...

The investigators are looking for a better way to prevent cervical cancer. This study is comparing two different methods to...

Read More